`Atty. Docket No.: GWLG-017US-CIP
`Response to Non-Final Office Action
`
`AMENDMENT TO THE SPECIFICATION
`
`Please amend [0023] of the Specification as follows:
`
`[0001] Figure 11 illustrates circulating concentrations of ZAG, glycodelin, BDNF, and
`
`CA-125 between untreated cases (n=35-60) and controls (n=12-26) with ROC curves.
`
`Circulating glycodelin (A) was significantly elevated (p=0.04l) in untreated cases
`
`compared to controls. Circulating ZAG (B) tended to be elevated (p=0.086) in untreated
`
`cases compared to controls. Circulating BDNF (C) was significantly higher (p=0.0008) in
`
`untreated cases compared to controls while circulating concentrations of CA125 (D) did
`
`not reach statistical significance (p=0.626). Glycodelin, ZAG, BDNF, and CA-125
`
`produced ROC curves with an AUC of 0.70 (p=0.040), 0.66 (p=0.085), 0.73 (p<0.001),
`
`and 0.47 (p=0.622), respectively. Statistically significant differences are denoted by an
`
`asterisk (*) above the graph (* p<0.05; *** p<0.001). Sensitivity vs specificity plots are
`
`provided in E). Whiskers on the box plots represent the 5th and 95th percentiles, while the
`
`lower limit of the box lower quartile and the upper limit is the upper quartile. The line
`
`within the box is the median of the data. Normally distributed data are portrayed as an
`
`aligned dot plot with error bars representing standard deviation from the mean;
`
`EDC_LAW\ 1826206\1
`
`2
`
`



